N2 PHARMACEUTICALS LTD
Research - Roslin, Scotland, United Kingdom
N2 PHARMACEUTICALS LTD Employees
N2 PHARMACEUTICALS LTD Senior Management
N2 PHARMACEUTICALS LTD Details
- Medical Research Scotland PhD studentship award winners - 2020- SMART Scotland Grant winners - 2018- Animal Health Investment Europe showcase finalists - London 2018- Informa Disruptors & innovators report 2018 Top 20 Animal Health start-upsN2 Pharmaceuticals has developed and patented a proprietary method to extract bioactive peptides (N2-01) from Mytilus edulis (Blue mussels).N2-01 has already been used in 25,000+ farm and companion animals in Russia and is proven to reduce mortality in multiple conditions associated with endothelial dysfunction, including Porcine circovirus type 2.In studies to date, N2-01 has been shown to significantly reduce endothelial dysfunction and vascular leakage in human endothelial cells.N2-01 also reduced (by 2.5 times) in vitro levels of interleukin-6, a protein that stokes the immune response and has been prominent in patients with COVID-19 and is a diagnostic/prognostic biomarker for sepsis/ARDS.Now based in Edinburgh, N2 Pharmaceuticals intend to repurpose N2-01 from animal health applications to treat a number of acute human diseases associated with endothelial dysfunction including COVID-19, ARDS and sepsis.
N2 PHARMACEUTICALS LTD Technologies
Other
Mobile Friendly